FI931801A0 - Peptid-inhibitorer av hi-virusreplikation - Google Patents

Peptid-inhibitorer av hi-virusreplikation

Info

Publication number
FI931801A0
FI931801A0 FI931801A FI931801A FI931801A0 FI 931801 A0 FI931801 A0 FI 931801A0 FI 931801 A FI931801 A FI 931801A FI 931801 A FI931801 A FI 931801A FI 931801 A0 FI931801 A0 FI 931801A0
Authority
FI
Finland
Prior art keywords
virusreplikation
inhibitorer
peptid
hiv replication
oligopeptide
Prior art date
Application number
FI931801A
Other languages
English (en)
Other versions
FI931801A (fi
Inventor
Martin Sumner-Smith
Richard W Barnett
Lorne S Reid
Nahum Sonenberg
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Publication of FI931801A0 publication Critical patent/FI931801A0/fi
Publication of FI931801A publication Critical patent/FI931801A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI931801A 1990-10-24 1993-04-21 Peptid-inhibitorer av hi-virusreplikation FI931801A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60295390A 1990-10-24 1990-10-24
PCT/CA1991/000378 WO1992007871A1 (en) 1990-10-24 1991-10-23 Peptide-based inhibitors of hiv replication

Publications (2)

Publication Number Publication Date
FI931801A0 true FI931801A0 (fi) 1993-04-21
FI931801A FI931801A (fi) 1993-04-21

Family

ID=24413440

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931801A FI931801A (fi) 1990-10-24 1993-04-21 Peptid-inhibitorer av hi-virusreplikation

Country Status (11)

Country Link
EP (1) EP0554284B1 (fi)
JP (1) JPH06501938A (fi)
AT (1) ATE146483T1 (fi)
AU (1) AU660947B2 (fi)
CA (1) CA2092075A1 (fi)
DE (1) DE69123754T2 (fi)
DK (1) DK0554284T3 (fi)
ES (1) ES2095959T3 (fi)
FI (1) FI931801A (fi)
GR (1) GR3022838T3 (fi)
WO (1) WO1992007871A1 (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
AU4037793A (en) * 1992-04-23 1993-11-29 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2152387C (en) * 1992-12-22 1998-10-27 Michael Twist (Deceased) Synergistic anti-viral compositions
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
CA2152373C (en) * 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
US5627194A (en) * 1993-11-17 1997-05-06 Allelix Biopharmaceuticals Inc. Anti-viral guanidino-substituted compounds
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
AU6972798A (en) * 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
DK2364734T3 (en) 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
CA2458677A1 (en) * 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
DK1755660T3 (da) 2004-05-07 2010-07-19 Univ North Carolina Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
EP1851247A2 (en) 2005-02-15 2007-11-07 Thymon L.L.C. Methods and compositions for impairing multiplication of hiv-1
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ560799A (en) 2005-03-03 2009-10-30 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
US8518414B2 (en) 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2010141845A2 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
JP2015533117A (ja) 2012-08-31 2015-11-19 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル インスリン様成長因子１（ｉｇｆ−１）を増強または阻害するためのモノクローナル抗体
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
ES2095959T3 (es) 1997-03-01
AU660947B2 (en) 1995-07-13
DE69123754D1 (de) 1997-01-30
GR3022838T3 (en) 1997-06-30
ATE146483T1 (de) 1997-01-15
CA2092075A1 (en) 1992-04-25
AU8725991A (en) 1992-05-26
DE69123754T2 (de) 1997-04-03
EP0554284A1 (en) 1993-08-11
WO1992007871A1 (en) 1992-05-14
DK0554284T3 (da) 1997-01-06
FI931801A (fi) 1993-04-21
JPH06501938A (ja) 1994-03-03
EP0554284B1 (en) 1996-12-18

Similar Documents

Publication Publication Date Title
FI931801A (fi) Peptid-inhibitorer av hi-virusreplikation
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
BR9205818A (pt) Composições azeotrópicas de 1,1,2,2-tetrafluororetano e semelhantes.
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
NO964966L (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ITRM920237A0 (it) Perfezionato impiego di medicinali broncodilatatori b2.
ATE169822T1 (de) Behandlung von herpesvirus infektion
ES2123156T3 (es) Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
PT789590E (pt) Imunopotenciacao induzida por quitosano
ES2089186T3 (es) Reflectores de pelicula de magnesio.
DE69330268D1 (de) Hämoregulierende peptide
ATE184787T1 (de) Therapeutische kombinationen
DE69514928D1 (de) Gegen protozoen wirksamezyklische tetrapeptide
ES2081097T3 (es) Vacuna contra los nematodos.
WO1999058638A3 (en) Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
NO931503L (no) Peptidbaserte inhibitorer av hiv-replikasjon
ATE238062T1 (de) Hemmung von hiv-infektion
ES2073286T3 (es) Productos cosmeticos estables.
SE9702242D0 (sv) Vaccine compositions V
FR2724845B1 (fr) Compositions de muramyl peptides capables d'inhiber jusqu'a 100% la replication d'un virus de l'immuno-deficience acquise, tel que le vih
FI930519A (fi) Peptider foer blokering av infektioner orsakade av hiv-virus samt foerfarande foer deras anvaendnig

Legal Events

Date Code Title Description
FD Application lapsed